跳至主要内容
临床试验/IRCT2014012616374N1
IRCT2014012616374N1已完成未知

The effect of bumetanide on positive , negative and cognitive symptoms of schizophrenic patients

Vice chancellor for research, university of Social Welfare & Rehabilitation sciences0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 55 years(—)
性别
All

入选标准

  • inclusion criteria: (1) Diagnosis of schizophrenia at any subtype according to DSM-IV diagnosis an statistical manual of mental disorders, 4th edition (2) aged 20 to 70 years (3) disease duration for at least 3 years (4) had a total score of at least 70 on the positive and negative syndrome scale(PANSS) (5) had persistent negative or considerable cognitive symptoms, that are equivalent with at least 20 and 15 score on the negative and cognitive subscales of PANSS, respectively. Exclusion criteria were: patients with a (1) documented fluctuation in symptoms (2) uncontrollable significant conditions (3) As well as concurrent history of significant psychiatric (except schizophrenia), cardiovascular, renal, hepatic, convulsive disorders or substance abuse.

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, university of Social Welfare & Rehabilitation sciences

相似试验

The effect of bumetanide on schizophrenia patients | 临床试验